An investigational triple hormone-receptor agonist studied in phase 2 trials for obesity and metabolic outcomes.
Pre-loaded with a typical Retatrutide vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for Retatrutide. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 1 mg – 12 mg | once weekly | subcutaneous | Phase 2 obesity trial maintenance dose arms (Jastreboff et al., NEJM 2023) Documented maintenance arms included 1, 4, 8, and 12 mg once weekly after structured escalation for higher doses. |
| 500 mcg – 12 mg | once weekly (study-defined) | subcutaneous | Phase 1b multiple-ascending-dose work in type 2 diabetes (LY3437943) Early clinical development explored weekly dosing and dose-dependent metabolic effects; follow the primary paper for cohort schedules. |
People searching this page also look for: retatrutide peptide dosage, retatrutide peptide dosage chart, reta peptide dosage, reta peptide dosage chart, retatrutide peptide dosage schedule, retatrutide peptide dosage calculator, peptide retatrutide dosage, what is the dosage for retatrutide peptide.
Retatrutide (LY3437943) is an investigational peptide agonist engineered to activate three receptors in the incretin/glucagon family: GIP, GLP-1, and glucagon receptors. It has been evaluated in company-sponsored clinical trials, including a prominent phase 2 obesity study published in the New England Journal of Medicine and earlier multiple-ascending-dose work in type 2 diabetes.
Researchers focus on retatrutide because dual and triple agonists extend the pharmacology already established for GLP-1 receptor agonists. In the phase 2 obesity trial, once-weekly subcutaneous escalation regimens produced substantial, dose-dependent mean body-weight reductions over 48 weeks compared with placebo, alongside metabolic marker changes typical of this class. Gastrointestinal adverse events were the most frequently discussed tolerability theme, consistent with incretin mimetics.
Educational dosage content should cite trial arms and titration schedules as documented research protocols. Retatrutide remains investigational for the indications studied in those papers and is not framed here as consumer guidance. Research-use discussions of vial sizes outside formal trials must stay clearly separated from labeled clinical development doses.
Retatrutide simultaneously engages GIP receptor, GLP-1 receptor, and glucagon receptor pathways. GLP-1 receptor activation is associated with enhanced glucose-dependent insulin secretion, slowed gastric emptying, and central appetite signaling. GIP receptor activity adds another incretin axis that may support insulinotropic and adipose-tissue effects in combination regimens. Glucagon receptor engagement is explored for energy-expenditure and hepatic lipid-metabolism contributions. The triple design aims to combine reduced energy intake with metabolic effects not fully captured by GLP-1 agonism alone.
obesity clinical research · type 2 diabetes · incretin pharmacology · body-weight regulation · cardiometabolic markers
Endocrinology and obesity-medicine trialists, metabolic pharmacologists, and translational teams comparing multi-receptor agonists with semaglutide- or tirzepatide-class agents. Academic groups analyze body-composition and liver-fat secondary endpoints. This audience is clinical-research oriented rather than cosmetic or injury-repair focused.
Follow manufacturer or trial pharmacy instructions for investigational product. Research lyophilizates are typically kept refrigerated, protected from light; reconstituted multi-dose research vials are refrigerated and timed to supplier stability limits. Do not freeze reconstituted solutions unless a COA explicitly allows it.
Formal trials study retatrutide as monotherapy against placebo or active comparators, not as part of informal peptide stacks. Combining with other incretin agents would duplicate pathway stimulation and is outside evidence-based research design. Lifestyle and background diabetes medications in trials are protocol-defined, not ad-hoc stacks.
The questions people actually search for, answered plainly.
In the landmark phase 2 obesity trial, participants received once-weekly subcutaneous retatrutide with maintenance doses of 1 mg, 4 mg, 8 mg, or 12 mg after escalation at higher strengths. Those figures are documented clinical-research arms, not a consumer recommendation. Always cite the primary NEJM protocol when discussing dose.
Trial product is pharmacy-prepared; research vials sold as lyophilized powder require label-specific diluent volumes. Choose a diluent volume that makes weekly mg doses easy to measure on an insulin syringe (for example, concentrating so that 0.1-0.5 mL matches the intended mg). Calculate from vial_mg / mL.
Clinical development uses weekly, not daily, dosing. Dividing a weekly mg amount into daily micro-doses is not how the phase 2 obesity protocol was written. Educational charts should show mg per week and titration steps.
A literature-faithful chart lists escalation steps toward 4, 8, or 12 mg weekly maintenance, including the lower 1 mg arm. Higher-dose groups in phase 2 used gradual increases every four weeks to improve gastrointestinal tolerability. Reproduce numbers from the peer-reviewed methods section.
In the 48-week phase 2 obesity study, mean weight-change curves separated over months, with large effects reported by week 48 at higher doses. Early gastrointestinal symptoms, when they occur in incretin trials, often appear during escalation. Timelines are trial endpoints, not guarantees for any individual.
Retatrutide was designed as a long-acting molecule compatible with once-weekly subcutaneous dosing. Exact terminal half-life values should be taken from clinical pharmacology sections of sponsor publications rather than informal blogs.
Pivotal studies evaluate it alone within controlled backgrounds. Stacking with other GLP-1 or GIP agents is not an evidence-based research protocol and may compound mechanism-overlapping effects. Educational sites should discourage casual polypharmacy framing.
mg_dose = concentration_mg_per_mL x mL_drawn. If a 20 mg vial is reconstituted with 2 mL, concentration is 10 mg/mL, so 0.4 mL provides 4 mg. Use a calculator and dual-check units before any research preparation.
Primary literature on Retatrutide. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides